Interaction of the T cell receptor (TCR) with an MHC-antigenic peptide complex results in
changes at the molecular and cellular levels in T cells. The outside environmental cues are …

Although notable progress has been made on novel cancer treatments, the overall survival
rate and therapeutic effects are still unsatisfactory for cancer patients …

Malignant cells utilize diverse strategies that enable them to thrive under adverse conditions
while simultaneously inhibiting the development of anti-tumor immune responses. Hostile …

Since the mid-1990s, dendritic cells have been used in clinical trials as cellular mediators for
therapeutic vaccination of patients with cancer. Dendritic cell-based immunotherapy is safe …

Cancer immunotherapy attempts to harness the power and specificity of the immune system
to treat tumours. The molecular identification of human cancer-specific antigens has allowed …

During the past decades, anticancer immunotherapy has evolved from a promising
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now …

The past decade has seen tremendous developments in novel cancer therapies through the
targeting of tumor-cell-intrinsic pathways whose activity is linked to genetic alterations and …

Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective
antitumor immune response against tumor antigens and was first explored in a clinical trial …

The accumulation of tumor infiltrating lymphocytes (TILs) in ovarian cancer is prognostic for
increased survival while increases in immunosuppressive regulatory T-cells (Tregs) are …

Whole tumor cell lysates (TCL) have been implemented as tumor antigens for cancer
vaccine development, although clinical outcomes of TCL-based antitumor immunotherapy …